MediWound Ltd.

MDWD

Healthcare Biotechnology

MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024.

Revenue
−45.8%
EPS
+53.7%
Free cash flow
−49.9%
Total debt
+51.8%

Quarter to June 2026, against a year earlier

14.25 0.92 +6.90%
Market cap
$184.0M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
5/9
Net debt / EBITDA
2.3×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

5 5 4 3
ROE
0.00% (63.49%) 0.00% (75.42%)
ROA
(24.36%) (29.90%) (35.04%) (29.06%)
ROIC
0.00% 0.00% 0.00% (6,551.77%)
Return on Tangible Assets
(34.34%) (45.14%) (51.40%) (44.09%)
Average Days of Receivables
105.29 58.78 69.27 107.47
Free Cash Flow per Share
(1.69) (1.90) (1.95) (2.21)
Free Cash Flow
(18.60) (21.63) (25.13) (28.53)
Other line items

Show all line items

Columns are period end dates